Galantamine: A new Alzheimer drug with a past life

Annals of Pharmacotherapy

Volumn 35, Issue 11, 2001, Pages 1406-1413

  Pearson, V E ^a  

^a CVS Pharmacy 4429 ^*  (United States)

Author keywords

Alzheimer disease; Galantamine

Indexed keywords

ALCURONIUM; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; NICOTINIC AGENT; PHYSOSTIGMINE; RIVASTIGMINE; TACRINE; TUBOCURARINE CHLORIDE;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG RECEPTOR BINDING; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; MOUSE; NEUROMUSCULAR BLOCKING; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SYMPTOMATOLOGY;

EID: 0035149931     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A092     Document Type: Review

References (39)

1. About a peculiar disease of the cerebral cortex
2. Alzheimer's: Unlocking the mystery
3. Alkaloids of Galanthus woronowi. II. Isolation of a new alkaloid
4. Enzyme immunoassays for the quantitative determination of galanthamine
5. Homer's Moly identified as Galanthus nivalis L.: Physiologic antidote to stramonium poisoning
6. The synthesis of galanthamine
7. Effects of galanthamine on the acetylcholine sensitivity of skeletal musculature
8. Cholinesterase inhibition by galanthamine and lycoramine
9. Neuronal nicotinic acetylcholine receptors as novel drug targets
10. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons
11. Physostigmine and galanthamine: Probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells
12. Galanthamine: Pharmacokinetics, tissue distribution and cholinesterase inhibition in brains of mice
13. Pharmacokinetics of galanthamine (a long acting anticholinesterase drug) in anaesthetized patients
14. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition
15. Pharmacokinetics of galanthamine hydrobromide after single subcutaneous and oral dosage in humans
16. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6
17. In vitro metabolism of galanthamine hydrobromide (Nivalin) by rat and rabbit liver homogenate
18. Inhibition of acetylcholinesterase activity in human brain tissue and erythrocytes by galanthamine, physostigmine and tacrine
19. Antagonistic effect of nivalin (galanthamine) versus morphine upon the respiratory center
20. The clinical application of nivalin as an antidote of curari
21. Clinical experiences with diallylnortoxiferene and the curare antidote galanthamine
22. Nivalin (galanthamine hydrobromide), an additional decurarizing agent. Some introductory observations
23. Experiences with Galanthamine hydrobromide as curare antagonist
24. Treatment of respiratory depression with the anticholinesterase drug galanthamine hydrobromide
25. Reversal of central anticholinergic syndrome by galanthamine
26. The cholinergic hypothesis of geriatric memory dysfunction
27. A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice
28. Various acetylcholinesterase inhibitors and passive avoidance behavior in nucleus basalis-lesioned rats
29. Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease
30. Galanthamine hydrobromide in the treatment of senile dementia of Alzheimer's type
31. Galanthamine treatment in Alzheimer's disease
32. Galantamine in AD: A 6-month randomized placebo-controlled trial with a 6-month extension
33. A 5-month randomized placebo-controlled trial of galantamine in AD
34. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial
35. Chronic treatment of old rats with donepezil or galantamine: Effects on memory, hippocampal plasticity and nicotinic receptors
36. Changes in cardiac rhythm with galanthamine hydrobromide
37. Intravenous nicotine in Alzheimer's disease: A pilot study
38. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease